MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ('Annovis' or the 'Company'), a late-stage clinical ...

Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure ...

PharmaEssentia is looking to expand the reach of its FDA-approved rare blood cancer treatment Besremi to another rare blood ...

PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

As a political scientist, Nuhu Yaqub devoted his intellectual ambition towards the actualisation of better national ...

Learn about clinical trials, from preclinical studies to Phase IV trials. Explore the different clinical trial phases (I-III) ...

Veliparib plus temozolomide did not significantly extend overall survival in patients with newly diagnosed, ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to ...

Percheron Therapeutics' board of directors has written a letter to shareholders following failure of its phase 2b trial.

Researchers have applied AI to every step of the drug development process. But this might not be enough to design safe and ...

More than three years after Novartis’ plan for a speedy approval for intrathecal Zolgensma was thwarted by an FDA requirement ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...